Affiliation:
1. Schering-Plough Research Institute, Kenilworth, New Jersey 07033
Abstract
ABSTRACT
Real-time quantitative PCR was used to measure expression levels of genes encoding efflux pumps,
ERG11
and two control genes,
ACT1
and
PMA1
, in a collection of 14 fluconazole-susceptible
Candida albicans
isolates. For each gene, average expression levels and variations within the population were determined. These values were then used as reference points to make predictions about the molecular basis of resistance in 38 clinical isolates (the majority of which were resistant to fluconazole) obtained from 18 patients treated with posaconazole for refractory oropharyngeal candidiasis. For each of the 38 isolates, the expression levels of genes encoding efflux pumps,
ERG11
and the control genes, were measured as above. Comparison of the two data sets revealed that expression of
ACT1
and
PMA1
did not vary significantly between the two sets of isolates. In contrast,
MDR1, ERG11
,
CDR1
, and
CDR2
were overexpressed in 3, 4, 14, and 35, respectively, of the isolates from patients treated with azoles. In addition to these changes, the patient isolates all had at least one and often multiple missense mutations in
ERG11
. Select
ERG11
alleles were expressed in
Saccharomyces cerevisiae
; all of the alleles tested conferred reduced susceptibility to fluconazole. Despite both the increases in pump expression and the
ERG11
mutations, only one of the patient isolates exhibited a large decrease in posaconazole susceptibility.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference20 articles.
1. In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against
Aspergillus
and
Candida
2. Canuto, M. M., and F. G. Rodero, 2002. Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis.2:550-563.
3. Li, X., N. Brown, A. S. Chau, J. L. López-Ribot, C. A. Mendrick, D. Loebenberg, R. S. Hare, B. J. DiDomenico, and P. M. McNicholas. 2004. Changes in susceptibility to posaconazole (POS) in clinical isolates of Candida albicans. J. Antimicrob. Chemother.53:74-80.
4. Transcriptional Analyses of Antifungal Drug Resistance in
Candida albicans
5. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. Ramaekers, F. C. Odds, and H. V. Bossche. 1999b. Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology145:2701-2713.
Cited by
154 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献